亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer

医学 乳腺癌 肿瘤科 内科学 癌症 新辅助治疗 事件(粒子物理) 残余物 风险评估 量子力学 算法 计算机安全 物理 计算机科学
作者
W. Fraser Symmans,Christina Yau,Yunn-Yi Chen,Ronald Balassanian,Molly Klein,Lajos Pusztai,Rita Nanda,Barbara A. Parker,Brian Datnow,Gregor Krings,Shi Wei,Michael D. Feldman,Xiuzhen Duan,Beiyun Chen,Husain Sattar,Laila Khazai,Jay Zeck,Sharon B. Sams,Paulette Mhawech‐Fauceglia,Mara H. Rendi
出处
期刊:JAMA Oncology [American Medical Association]
卷期号:7 (11): 1654-1654 被引量:74
标识
DOI:10.1001/jamaoncol.2021.3690
摘要

Importance

Residual cancer burden (RCB) distributions may improve the interpretation of efficacy in neoadjuvant breast cancer trials.

Objective

To compare RCB distributions between randomized control and investigational treatments within subtypes of breast cancer and explore the relationship with survival.

Design, Setting, and Participants

The I-SPY2 is a multicenter, platform adaptive, randomized clinical trial in the US that compares, by subtype, investigational agents in combination with chemotherapy vs chemotherapy alone in adult women with stage 2/3 breast cancer at high risk of early recurrence. Investigational treatments graduated in a prespecified subtype if there was 85% or greater predicted probability of higher rate of pathologic complete response (pCR) in a confirmatory, 300-patient, 1:1 randomized, neoadjuvant trial in that subtype. Evaluation of a secondary end point was reported from the 10 investigational agents tested in the I-SPY2 trial from March 200 through 2016, and analyzed as of September 9, 2020. The analysis plan included modeling of RCB within subtypes defined by hormone receptor (HR) andERBB2 status and compared control treatments with investigational treatments that graduated and those that did not graduate.

Interventions

Neoadjuvant paclitaxel plus/minus 1 of several investigational agents for 12 weeks, then 12 weeks of cyclophosphamide/doxorubicin chemotherapy followed by surgery.

Main Outcomes and Measures

Residual cancer burden (pathological measure of residual disease) and event-free survival (EFS).

Results

A total of 938 women (mean [SD] age, 49 [11] years; 66 [7%] Asian, 103 [11%] Black, and 750 [80%] White individuals) from the first 10 investigational agents were included, with a median follow-up of 52 months (IQR, 29 months). Event-free survival worsened significantly per unit of RCB in every subtype of breast cancer (HR-positive/ERBB2-negative: hazard ratio [HZR], 1.75; 95% CI, 1.45-2.16; HR-positive/ERBB2-positive: HZR, 1.55; 95% CI, 1.18-2.05; HR-negative/ERBB2-positive: HZR, 2.39; 95% CI, 1.64-3.49; HR-negative/ERBB2-negative: HZR, 1.99; 95% CI, 1.71-2.31). Prognostic information from RCB was similar from treatments that graduated (HZR, 2.00; 95% CI, 1.57-2.55; 254 [27%]), did not graduate (HZR, 1.87; 95% CI, 1.61-2.17; 486 [52%]), or were control (HZR, 1.79; 95% CI, 1.42-2.26; 198 [21%]). Investigational treatments significantly lowered RCB in HR-negative/ERBB2-negative (graduated and nongraduated treatments) andERBB2-positive subtypes (graduated treatments), with improved EFS (HZR, 0.61; 95% CI, 0.41-0.93) in the exploratory analysis.

Conclusions and Relevance

In this randomized clinical trial, the prognostic significance of RCB was consistent regardless of subtype and treatment. Effective neoadjuvant treatments shifted the distribution of RCB in addition to increasing pCR rate and appeared to improve EFS. Using a standardized quantitative method to measure response advances the interpretation of efficacy.

Trial Registration

ClinicalTrials.gov Identifier:NCT01042379
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
XuchaoD完成签到,获得积分10
8秒前
8秒前
今后应助Liiiiiiiiii采纳,获得10
11秒前
顾矜应助科研通管家采纳,获得10
14秒前
Akim应助科研通管家采纳,获得10
14秒前
18秒前
38秒前
48秒前
1分钟前
小张完成签到 ,获得积分10
1分钟前
可耐的冰萍完成签到,获得积分10
1分钟前
充电宝应助干净涵梅采纳,获得10
1分钟前
1分钟前
1分钟前
1分钟前
1分钟前
李李发布了新的文献求助10
1分钟前
科研通AI5应助李李采纳,获得10
1分钟前
爱笑的毛衣完成签到,获得积分10
1分钟前
太叔丹翠完成签到 ,获得积分10
1分钟前
沉默白猫完成签到 ,获得积分10
1分钟前
2分钟前
sowhat完成签到 ,获得积分10
2分钟前
孙老师完成签到 ,获得积分10
2分钟前
盛事不朽完成签到 ,获得积分10
2分钟前
2分钟前
科研通AI2S应助科研通管家采纳,获得10
2分钟前
FashionBoy应助科研通管家采纳,获得10
2分钟前
羞涩的傲菡完成签到,获得积分10
2分钟前
2分钟前
Hung发布了新的文献求助10
2分钟前
2分钟前
Lyncon完成签到,获得积分10
2分钟前
Milton_z完成签到 ,获得积分0
2分钟前
Hung完成签到,获得积分10
2分钟前
tingyeh完成签到,获得积分10
3分钟前
3分钟前
两个我完成签到 ,获得积分10
3分钟前
3分钟前
3分钟前
高分求助中
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3990049
求助须知:如何正确求助?哪些是违规求助? 3532108
关于积分的说明 11256354
捐赠科研通 3270976
什么是DOI,文献DOI怎么找? 1805166
邀请新用户注册赠送积分活动 882270
科研通“疑难数据库(出版商)”最低求助积分说明 809228